Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)
Orphazyme A/S Company announcement No. 12/2021 Inside information Company Registration No. 32266355 Copenhagen – March 29, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company